|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0025266,
umls-concept:C0033085,
umls-concept:C0138741,
umls-concept:C0205210,
umls-concept:C0229671,
umls-concept:C0376358,
umls-concept:C0754659,
umls-concept:C1511790,
umls-concept:C1554184,
umls-concept:C1999216,
umls-concept:C2252854
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2006-4-7
|
|
pubmed:abstractText |
We determined whether the decrease in serum PSA seen with 5alpha-reductase inhibitors affects the clinical usefulness of PSA for prostate cancer screening using data from 2 dutasteride benign prostatic hyperplasia studies.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0022-5347
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
175
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1657-62
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16600723-Aged,
pubmed-meshheading:16600723-Aged, 80 and over,
pubmed-meshheading:16600723-Azasteroids,
pubmed-meshheading:16600723-Cholestenone 5 alpha-Reductase,
pubmed-meshheading:16600723-Humans,
pubmed-meshheading:16600723-Male,
pubmed-meshheading:16600723-Middle Aged,
pubmed-meshheading:16600723-Prostate-Specific Antigen,
pubmed-meshheading:16600723-Prostatic Hyperplasia,
pubmed-meshheading:16600723-Prostatic Neoplasms,
pubmed-meshheading:16600723-Reproducibility of Results
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride.
|
|
pubmed:affiliation |
Division of Urologic Surgery, Washington University, St. Louis, Missouri 63110, USA. andrioleg@msnotes.wustl.edu
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
